Navigation Links
Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Date:1/12/2010

NEW YORK, Jan. 12 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that it will present at the 12th Annual Needham Growth Stock Conference at the New York Palace Hotel. The Company's presentation is scheduled for 4:30 p.m. Eastern Time on January 14, 2010. David McDonald, Chief Financial Officer, will review the company's business strategy and recent corporate developments.

Delcath will offer a live video webcast of its presentation which may be accessed on the Investor Relations section of the Company's website at www.delcath.com. An archived replay of the presentation will be available for 30 days, also at www.delcath.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical device company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.

RELATED LINKS
http://www.delcath.com

'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems, Inc. Prices $30.6 Million Stock Offering
11. Delcath Systems Announces Completion of Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... DDS, and Randall Markarian, DDS, are co-chairs for the Illinois State Dental Society ... Friday-Saturday, July 15-16 at the Gateway Convention Center in Collinsville. , ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... Foundation, a not-for-profit organization responsible for clinical transfusion research programs and for the ... the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , ...
(Date:6/23/2016)... ... June 23, 2016 , ... SyncDog, Inc. ... mobile security software, is featured in the current issue of Silicon Review ... companies with innovative technology solutions and features them in their magazine. The magazine ...
(Date:6/23/2016)... Newark, NJ (PRWEB) , ... June 23, 2016 ... ... declared today’s Appellate Court ruling a victory for consumers seeking relief from the ... Div., Docket No. A2913-15T2 & A2929-15T2. , In their ruling ( ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... A key ... DC area, which is one of the best known examples of areas that lack ... amassed almost a thousand daily users. , Any participant within the marijuana industry, ...
Breaking Medicine News(10 mins):